TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 y. old, non or ex-smokers for \> 6 months~* Mild to moderate asthmatic in general good health~* On either low-dose inhaled corticosteroid or steroid naive~* No other asthma medication~* Regular sputum producer~* EOS more than 3% at randomization,~* FEV1 \> 70%~Exclusion Criteria:~* Respiratory infection within last 4 weeks~* Any condition that may affect the conduct of the study as per the investigators

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TPI ASM8 (Type: EXPERIMENTAL): ASM8 0.25mg
- ASM8 as TPI ASM8 (Type: EXPERIMENTAL): TPI ASM8 0.5mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Tamsulosin on Postoperative Urinary Retention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage II or greater pelvic organ prolapse in \> 1 vaginal compartment~* Plan for multicompartment native tissue vaginal repair (which would include any combination of uterosacral ligament suspension, sacrospinous ligament suspension, cystocele and/or rectocele repair, with or without hysterectomy and with or without concomitant mid-urethral sling) or vaginal closure with female pelvic medicine and reconstructive surgery (FPMRS) - trained surgeons at Wake Forest Baptist Health~* Participation in Enhanced-Recovery-After-Surgery protocol with plan for same-day hospital discharge~* Willing to remain compliant with Investigation Product (IP)~Exclusion Criteria:~* Intraoperative complication necessitating prolonged bladder drainage or placement of a vaginal pack x 24 hours (patients would exit study after randomization and will be excluded from the per-protocol analysis)~* Patients whose surgical plan would necessitate a voiding trial on postop day \>0~* Less than 21 years of age~* Unable to understand English~* Patients who are scheduled to undergo combined colorectal procedures such as rectopexy, sphincteroplasty~* Patient with known allergy to Tamsulosin or sulfa drugs~* Patients with upcoming cataract surgery~* Patient with orthostatic hypotension~* History of postvoid residual (PVR\>150) prior to surgery with prolapse reduction~* Patients with hypertension on alpha-blockers~* Single compartment prolapse repair (anterior or posterior repair only)~* Use of mesh for prolapse repair~* High tone pelvic floor dysfunction

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Tamsulosin (Type: EXPERIMENTAL): Patients in this arm will receive 10 days of 0.4 mg of oral tamsulosin once daily starting 5 days pre-operatively and continuing until all pills are completed.
- Placebo (Type: PLACEBO_COMPARATOR): Patients in this arm will receive 10 days of identical-appearing placebo once daily starting 5 days pre-operatively and continuing until all pills are completed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must be 18 to \< 65 years of age, at time of randomization~* Participants must be in good health, determined from medical history and no clinically significant findings from physical examination, 12-lead electrocardiogram (ECG), vital signs, and laboratory values~Exclusion Criteria:~* History or clinical evidence of conditions considered high risk for developing influenza-related complications~* History of confirmed influenza infection within 3 months prior to randomization.~* Febrile illness with or without respiratory symptoms~* History of malignancy within 5 years or participant is under evaluation for malignancy.~* Any condition or receipt of any medication contraindicating IM injection, as judged by the investigator.~* History of a severe allergic reaction with generalized urticaria, angioedema or anaphylaxis~* Participant has a clinically significant medical condition, physical exam finding, or abnormal laboratory result.~* Prior or planned receipt of any influenza vaccine for the upcoming season.~* Received any investigational agent within 90 days or within 5 half-lives of the investigational agent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- VIR-2482 (Dose 1) (Type: EXPERIMENTAL): None
- VIR-2482 (Dose 2) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Secondary Hyperparathyroidism in the Uremic Patient

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. \>18 years old~2. Secondary hyperparathyroidism; iPTH \> 350 pg/ml before any treatment or after 6 weeks without any treatment with vitamin D.~3. Chronic renal insufficiency receiving hemodialysis.~4. P-phosphate \< 1,8 mmol/l~5. P-calcium ion \< 1,25 mmol/l~6. Receiving maximal possible dose of calcium-based phosphate binder.~7. Accepting 2 x 6 weeks without vitamin D.~8. Safe anti conception in fertile women~9. Do not expect need of calcimimetics or parathyroidectomy during the next year.~10. Written informed consent.~Exclusion Criteria:~1. Malignancy~2. Disease or condition making the patient unable to participate~3. Expected lifetime less than one year.~4. Pregnancy and nursing~5. Allergic to contents of Zemplar or Etalpha~6. Currently receiving calcimimetics~7. Participating in other clinical intervention studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): alfacalcidol 16 weeks, 6 weeks wash out, paricalcitol 16 weeks
- 2 (Type: ACTIVE_COMPARATOR): paricalcitol ´16 weeks, 6 weeks wash out, alfacalcidol 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Radiographic or marker evidence of metastatic ovarian, breast, pancreatic, or colon disease~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Menopausal status not specified~* No history of any prior cancer~PRIOR CONCURRENT THERAPY:~* No prior therapy for metastatic disease

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metastatic Breast Cancer (Type: None): None
- Metastatic Ovarian Cancer (Type: None): None
- Metastatic Pancreatic Cancer (Type: None): None
- Metastatic Colon Cancer (Type: None): None
- Stage 3 Ovarian Cancer (Type: None): None
- Locally Advanced Pancreatic Cancer (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Stage Ta (any grade) transitional cell carcinoma of the bladder on basis of cystoscopy Recurrent disease no greater than T1 Must not be at high risk for upper tract (ureter or renal pelvic) transitional cell cancers~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not pregnant or nursing Fertile patients must use effective contraception No other prior malignancy in the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission No allergies to fluoroquinolones If allergic to penicillin or cephalosporin, must be able to take co-trimoxazole~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 28 days since prior intravesical therapy and recovered Endocrine therapy: Not specified Radiotherapy: At least 28 days since prior radiotherapy and recovered Surgery: Not specified Other: At least 3 months prior to cystoscopy since prior fluoroquinolones No concurrent fluoroquinolones No concurrent hemodialysis or peritoneal dialysis No concurrent probenecid or theophylline No concurrent antacids containing aluminum, magnesium or calcium, products containing iron or zinc, caffeine, cyclosporine, or warfarin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cipro (Type: EXPERIMENTAL): ciprofloxacin
- ceph (Type: EXPERIMENTAL): cephalexin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mechanical Diagnosis and Treatment and/or Steroid Injections for Lumbar Radiculopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* leg dominant pain secondary to lumbar disc protrusion confirmed on MRI with duration \> 3 months, at least one neurological sign and able to speak English and provide written informed consent.~Exclusion Criteria:~* Pregnancy and specific causes of LBP not directly related to herniated discs, progressive neurological signs and/or cauda equine syndrome, or contraindication for the use of corticosteroids or fluoroscopy. These features primarily represent patients who are not suitable for the interventions offered in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Wait list control - usual care - free to pursue other treatments prescribed by the patients family physician
- MDT +/- TESI (Type: EXPERIMENTAL): Exercise (MDT approach) and/or Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%). Patients will further classified into centraliser (group 2a) and non-centralising pain responses (group 2b). Group 2a: will continue with exercise (MDT approach). Group 2b: Patients with a non-centralising pain response will be offered Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under fluoroscopic guidance with contrast medium (Omni Pac 240). Two weeks after completion of the MDT or TESI intervention, patients will be reassessed and treated consistent with their response: 1) resolved: advice on remaining active; 2) centralising: daily exercises based on MDT principles; 3) non-centralising but significant less pain: advice to remain active, with respect for worsening leg pain; and 4) persisting high levels of pain and/or disability: advise to remain active as tolerated and consult family physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tritanium® Primary Acetabular Shell Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A. Patient has signed an IRB approved, study specific Informed Patient Consent Form.~* B. Patient is a male or non-pregnant female age 18 years or older at time of study device implantation.~* C. Patient has primary diagnosis of Non-Inflammatory Degenerative Joint Disease (NIDJD).~* D. Patient is a candidate for a primary cementless total hip replacement.~* E. Patient is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation.~Exclusion Criteria:~* F. Patient has a Body Mass Index (BMI) ≥ 40.~* G. Patient has an active or suspected latent infection in or about the affected hip joint at time of study device implantation.~* H. Patient has a neuromuscular or neurosensory deficiency, which limits the ability to evaluate the safety and efficacy of the device.~* I. Patient is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic disorder (e.g. Paget's Disease) leading to progressive bone deterioration.~* J. Patient is immunologically suppressed or receiving steroids in excess of normal physiological requirements (e.g. \> 30 days).~* K. Patient requires revision surgery of a previously implanted total hip replacement or hip fusion to the affected joint.~* L. Patient has a known sensitivity to device materials.~* M. Patient is a prisoner.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tritanium® Primary Acetabular Shell (Type: OTHER): Tritanium® Primary Acetabular Shell

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven metastatic adenocarcinoma of the colon or rectum Previously untreated OR Recurrent with a disease free period of at least 1 year Measurable or evaluable disease Tumor must be accessible for biopsy No brain metastasis~PATIENT CHARACTERISTICS: Age: Over 18 Performance status: SWOG 0-2 Life expectancy: Not specified Hematopoietic: Absolute granulocyte count greater than 1,000/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) (no greater than 3 times ULN if liver metastasis present) AST or ALT no greater than 2 times ULN (no greater than 5 times ULN if liver metastasis present) Renal: Creatinine no greater than 1.25 times ULN Cardiovascular: No myocardial infarction within the past year No congestive heart failure Other: No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for at least 6 months after study No medical, social, or psychological factor that would interfere with compliance~PRIOR CONCURRENT THERAPY: Biologic therapy: Prior adjuvant immunotherapy with monoclonal antibody 17-1A allowed No prior IM-862 Chemotherapy: At least 1 year since prior chemotherapy for patients with recurrent metastatic adenocarcinoma of the colon or rectum Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy No concurrent radiotherapy Surgery: Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Ketamine on Postoperative Clinical Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~1. Patients scheduled to undergo small and/or large partial bowel resection via laparotomy or laparoscopy~2. Willingness and ability to sign an informed consent document~3. No allergies to anesthetic or analgesic medications~4. 18 - 80 years of age~5. American Society of Anesthesiologists (ASA) Class I - III adults of either sex~Exclusion Criteria~1. Inability to comprehend the pain assessment tools~2. Patients with known allergy, hypersensitivity or contraindications to anesthetic or analgesic medications~3. Patients with clinically-significant heart disease including arrhythmias and significant hypertension, brain aneurysms, prior history of cerebral vascular accident (CVA), or chronic renal insufficiency~4. Prior abdominal surgery~5. History of abdominal carcinomatosis~6. History of radiation enteritis;~7. Patients with history of hepatic, renal, cardiac failure, organ transplant, or diabetes~8. Patients with seizures~9. Morbid obesity (body mass index \>40)~10. Pregnant or lactating women~11. Subjects with a history of alcohol or drug abuse within the past 3 months~12. Any other conditions or use of any medication which may interfere with the conduct of the study~13. Prophylactic Nasogastric Tube (NGT) use~14. Individuals with significant manic disorders including: schizophrenia, or bipolar disorder or psychosis~15. Individuals with asthma and/or thyroid diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Loading and Infusion:~Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate
- Ketamine low-dose (Type: ACTIVE_COMPARATOR): Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
- Ketamine high-dose (Type: ACTIVE_COMPARATOR): Loading: 1 mg/Kg Infusion: 10 mcg/kg/min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Atorvastatin on Viral Replication During Antiretroviral Treatment Interruption

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>= 18 years.~2. Patients with chronic infection by HIV-1 in stable highly active antiretroviral treatment (\>= 6 months).~3. Undetectable plasma viral load (\<50 copies/mL) in the last 3 determinations over the last 6 months.~4. CD4 \> 500 cells/mm\>=3 in the last two determinations.~5. Documented prior viral load at some time of \>15,000 copies/mL.~6. Women may not be of fertile age (defined as at least one year from menopause or undergoing any surgical sterilisation technique), or must undertake to use a barrier contraceptive method during the study.~7. Signature of the informed consent~Exclusion Criteria:~1. CD4 nadir \<= 200 cells/mm3.~2. Background of infections or other AIDS-defining pathology.~3. Intercurrent infections in the last 6 months.~4. Creatine kinase (CK) \>= 500 U/L.~5. AST or ALT \>= 3 times higher than the upper limit of normality.~6. Treatment with others statins, fibrates, macrolides or fluconazole in the last 3 months.~7. Pregnancy or breastfeeding~8. Patients participating in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): 4 semanas manteniendo el tratamiento antirretroviral e iniciar atorvastatina 40 mg/día. A la semana 4 interrupción HAART y aumentar a 80 mg/día de atorvastatina hasta la semana 32 de seguimiento
- B (Type: NO_INTERVENTION): 4 semanas manteniendo el tratamiento antirretroviral. A la semana 4 interrupción HAART hasta la semana 32 de seguimiento

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Molecular and Organizational Changes in the Human Oral Mucosa During Aging

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient requiring a classic dental surgery (extraction, implantology...) at the Toulouse University Hospital,~* Between the ages of 20 and 40 or between 70 and 90 years~Exclusion Criteria:~* Patient with gastrotomy probes or chemotherapy, palliative care (or with a life expectancy of less than 30 days),~* Patient with surgical contraindication: allergy to local anesthetics, major hemorrhagic risk: patient on unbalanced Anti Vitamin K, patient on new anticoagulants not relayed or not discontinued,~* Patient at high risk of infectious endocarditis~* Patient under safeguard of justice.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 20-40 years old (Type: EXPERIMENTAL): 33 patients between 20 and 40 years old
- 70-90 years old (Type: EXPERIMENTAL): 33 patients between 70 and 90 years old

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues